© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
EAU Annual Congress
Pembrolizumab/chemo regimen sustains efficacy in post–abiraterone/enzalutamide mCRPC
August 14, 2020
Response and survival rates with the immunotherapy-based regimen support ongoing phase 3 research with pembrolizumab in prostate cancer.
Holmium laser advances help propel progress in BPH, urinary stones
August 05, 2020
Holmium laser lithotripsy with Moses 2.0 is intended to enhance precision and versatility by optimizing laser energy transmission.
Darolutamide efficacy sustained in nonmetastatic CRPC patients with rapid PSA doubling time
July 30, 2020
A subgroup analysis of the pivotal phase 3 ARAMIS trial showed that the efficacy of darolutamide was sustained in patients with a rapid PSA double time.
5-year data sustain water vapor thermal therapy benefit in BPH-related LUTS
July 30, 2020
Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Thulium fiber laser shows efficiency advantage in experimental setting
July 29, 2020
Super-pulsed thulium fiber laser (TFL) has greater efficiency than a holmium:YAG laser, even when using the TFL with a smaller core-diameter fiber, according to preclinical findings.
Algorithm may predict health-related quality of life in patients with urolithiasis
July 28, 2020
The machine learning algorithm incorporates readily available clinical information.
Men on active surveillance for prostate cancer may benefit from Mediterranean diet
July 28, 2020
Mediterranean diet score was modestly associated with time to grade group progression.
Study reveals risk factors for upgrading in active surveillance for prostate cancer
July 27, 2020
“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.
Nephrectomy after immunotherapy can achieve complete response in selected patients
July 27, 2020
A study author said that “the long exposure [to immune checkpoint inhibitor therapy] results in challenging surgery.”
Paclitaxel-hyaluronic acid conjugate induces CR in 75% of patients with bladder CIS
July 24, 2020
Intravesical Oncofid P-B, a conjugate of paclitaxel and hyaluronic acid, is active in patients with carcinoma in situ of the bladder that is not responsive to bacillus Calmette-Guérin.